A survey of obstetric ultrasound uses and priorities for artificial intelligence-assisted obstetric ultrasound in low- and middle-income countries.

Journal: Scientific reports
PMID:

Abstract

Obstetric ultrasound (OBUS) is recommended as part of antenatal care for pregnant individuals worldwide. To better understand current uses of OBUS in low- and middle-income countries and perceptions regarding potential use of artificial intelligence (AI)-assisted OBUS, we conducted an anonymous online global survey. A total of 176 respondents representing 34 countries participated, including 41% physicians, 49% nurses or midwives, and 6% ultrasound technicians. Most had received OBUS training (72%), reported expertise (60%) and confidence (77%) in OBUS use, and had access to ultrasound (85%). Assessment of gestational age, fetal viability, fetal presentation, and multiple gestation were both the most common OBUS uses and among the most highly prioritized for AI-assisted OBUS development. Most respondents noted ultrasound access was important (84%) and agreed that OBUS improves quality of care (98%) and patient outcomes (97%). Of the 34% expressing reservations associated with using AI-assisted OBUS, healthcare providers not understanding the technology (71%), misdiagnosis (62%), and cost (59%) were the most common. Better understanding the OBUS user, the pregnant individual, and the context, and taking care to ensure responsible, sustainable, and inclusive development and use of AI-assisted OBUS will be critical to successful integration and implementation and to increasing access to OBUS.

Authors

  • Amy Sarah Ginsburg
    Clinical Trials Center, University of Washington, Seattle, WA 98115, USA. Electronic address: messageforamy@gmail.com.
  • Zylee Liddy
    Clinical Trials Center, University of Washington, Building 29, Suite 250, 6200 NE 74th Street, Seattle, WA, 98115, USA.
  • Eren Alkan
    Caption Health, GE HealthCare, San Mateo, CA, USA.
  • Kayla Matcheck
    Caption Health, GE HealthCare, San Mateo, CA, USA.
  • Susanne May
    Clinical Trials Center, University of Washington, Building 29, Suite 250, 6200 NE 74th Street, Seattle, WA, 98115, USA.